Newsletter Signup | Join Community
Could Neoadjuvant Immunotherapy be The Next Major Treatment Advance for Early Stage Non-Small Cell Lung Cancer?
Keytruda immunotherapy has become a standard of care for PD-1 + NSCLC: 5 Year survival data updated at ASCO 2019
TAPUR study suggests CDKN2A + lung cancer can be targeted with breast cancer drug Ibrance
Lung Cancer: Still Number One
Lobrena - a third generation ALK inhibitor drug with excellent CNS activity
Surgery, radiation, and systemic chemotherapy - precision cancer medicines are all used to treat stage IIIA NSCLC
Gilotrif as a single agent or in combination improves survival in EGFR + NSCLC.
Treatment of multiple myeloma and cancers that spread to bone all benefit from XGEVA treatment.
Understand the role of PET/CT scanning in the management of Non-Small Cell Lung Cancer.
IMPower133 clinical trial leads to Tecentriq being first new approved initial treatment for SCLC in years.
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and work to…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…